Lupin’s stock fell to a seven-week low of ₹2,273.90 on Monday as investors reacted to potential US market headwinds. Although the company reported a 16% profit jump for the June quarter, concerns over new competition in key US drugs like Tolvaptan led analysts to lower growth expectations. The market is pricing in reduced profitability for the coming quarters as the US product mix shifts.
Lupin’s stock price saw a sharp decline on Monday, touching an intra-day low of ₹2,273.90 on the BSE, representing a 4% drop. This movement marks the stock’s lowest point in seven weeks. The decline comes despite the pharmaceutical major reporting a 16% year-on-year increase in profit after tax to ₹1,417 crore for the quarter ended June 30, 2026.
Why Investors Are Cautious Despite Profit Growth
While the company posted a strong revenue increase of 33.3% to ₹8,217 crore, market participants appear to be looking past these numbers, focusing instead on future risks. The primary concern among investors is the expected surge in competition within the US market for specific high-value products.
Lupin’s US business has been a significant driver of its recent performance, with North American sales jumping 43% to $366 million in the first quarter, largely supported by sales of Tolvaptan. However, the company and market analysts have indicated that this momentum is unlikely to continue at the same pace. The entry of new competitors like Apotex and Teva into the Tolvaptan market, with potentially more rivals arriving by September 2026, is expected to reduce market share and force price cuts.
Outlook for Profitability and US Growth
Financial analysts have begun adjusting their expectations for Lupin. The consensus view is that the US growth trajectory will moderate as generic competition erodes the pricing advantage of current assets. Projections now suggest that the quarterly revenue run-rate from the US, which stood at $366 million in the latest quarter, may settle into a range of $250 million to $280 million in the coming quarters.
This shift is causing concern regarding future profit margins. Because the company’s recent success was tied to specific products now facing pressure, the overall earnings growth for the next two years is expected to be flat or slightly negative. Several brokerage firms have adjusted their target prices downward, citing that the stock currently trades at a valuation that may not account for the expected stagnation in earnings growth.
Recent Market Underperformance
The current price correction adds to a wider trend of underperformance for Lupin compared to the broader market. Over the last month, the stock has shed roughly 9% of its value, even as the BSE Sensex recorded gains. The healthcare sector has generally seen positive momentum, but Lupin has struggled to keep pace, indicating that specific company-related risks are weighing more heavily on investor sentiment than sector-wide trends.
Investors will likely track the company's US revenue run-rate in the upcoming quarterly reports to see if these fears materialize. The ability of Lupin to launch new products from its pipeline to offset the decline in current high-value drugs will be a key factor for the business in the near term. Managing the transition to a more competitive pricing environment while maintaining margin stability will remain the central focus for observers.